P637 Risks of Development of COVID-19 among Patients with Inflammatory Bowel Disease

Kappelman, M.(1);Zhang, X.(1);Lewis, J.(2);Melmed, G.(3);Siegel, C.(4);Cerciello, E.(5);Dobes, A.(5);Weaver, A.(5);Weisbein, L.(6);Long, M.(7);

(1)University of North Carolina, Division of Pediatric Gastroenterology- Department of Pediatrics, Chapel Hill, United States;(2)University of Pennsylvania, Medicine, Philadelphia, United States;(3)Cedar Sinai, Medicine, Los Angeles, United States;(4)Dartmouth, Medicine, Hanover, United States;(5)Crohn's & Colitis Foundation, Research, New York, United States;(6)University of North Carolina, Gastroenterology, Chapel Hill, United States;(7)University of North Carolina, Medicine, Chapel Hill, United States;


Patients with inflammatory bowel disease (IBD) may be at risk for development of COVID-19 infection due to innate immune dysfunction and/or immunosuppressive medication use. We sought to 1) evaluate the incidence of COVID-19 infection in a large, U.S. cohort of patients with IBD and 2) evaluate associations between demographic, clinical, and treatment-related factors and the development of COVID-19 infection.


Participants in 3 adult IBD studies sponsored by the Crohn’s & Colitis Foundation, IBD Partners, IBD QORUS (Improving the Quality of Care for Adults with Inflammatory Bowel Disease), and SPARC IBD (Study of a Prospective Adult Research Cohort with IBD), were invited to participate in a prospective, direct-to-patient cohort study about COVID-19 from April 23, 2020 until August 30, 2021.   Each cohort received online surveys with questions on comorbidities, medication utilization and development of laboratory confirmed COVID-19 at times 0, 2, 4, 6, 8 weeks and then every 6 months. We calculated the incidence rate of COVID-19 and performed bivariate and multivariate analyses to describe associations between age, immunosuppression use, obesity,  and race on the development of COVID-19.


A total of 3953 patients with IBD were followed for a mean duration of 212 days (SD 157). Demographic, clinical and treatment factors are shown in Table 1.  A total of 103 individuals developed COVID-19 during follow up (2.6%, rate of 45 per 1,000 person-years). Severity of infection was generally mild. Clinical characteristics were similar among those who developed COVID-19 as compared to not. African American race was associated with incident COVID-19 infection (OR 3.37, 95% CI 1.18-9.59). Immunosuppression use was not associated with development of COVID-19 (OR 1.19, 95% CI 0.72-1.75), nor was age (OR 1.00, 95% CI 0.99-1.02), nor obesity (OR 1.01, 95% CI 0.61-1.66).


The overall incidence of COVID-19 infection among this large U.S. cohort of IBD patients was relatively low.  Immunosuppression use did not increase the risk of development of COVID-19.  Therapeutic management of IBD should not be altered to prevent a risk of developing COVID-19.